Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis.
about
A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activityImmune-related zinc finger gene ZFAT is an essential transcriptional regulator for hematopoietic differentiation in blood islandsGenome-wide data reveal novel genes for methotrexate response in a large cohort of juvenile idiopathic arthritis casesCo-regulatory expression quantitative trait loci mapping: method and application to endometrial cancer.Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association data.Genome-wide association studies in pharmacogenomics: successes and lessons.Identification of shared genes and pathways: a comparative study of multiple sclerosis susceptibility, severity and response to interferon beta treatment.Candidate gene study of TRAIL and TRAIL receptors: association with response to interferon beta therapy in multiple sclerosis patients.Key genes for modulating information flow play a temporal role as breast tumor coexpression networks are dynamically rewired by letrozole.Association of CD58 Polymorphism with Multiple Sclerosis and Response to Interferon ß Therapy in A Subset of Iranian PopulationZfat-deficiency results in a loss of CD3ζ phosphorylation with dysregulation of ERK and Egr activities leading to impaired positive selection.Roles of white matter in central nervous system pathophysiologies.Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis.Endogenous, or therapeutically induced, type I interferon responses differentially modulate Th1/Th17-mediated autoimmunity in the CNS.An integrated approach to design novel therapeutic interventions for demyelinating disordersPharmacogenomic study in patients with multiple sclerosis: Responders and nonresponders to IFN-β.The Nuclear Zinc Finger Protein Zfat Maintains FoxO1 Protein Levels in Peripheral T Cells by Regulating the Activities of Autophagy and the Akt Signaling Pathway.ZFAT gene variant association with multiple sclerosis in the Arabian Gulf population: A genetic basis for gender-associated susceptibilityIFN-beta pharmacogenomics in multiple sclerosis.Glutamate and ATP signalling in white matter pathology.Determinants of interferon β efficacy in patients with multiple sclerosis.Sieving treatment biomarkers from blood gene-expression profiles: a pharmacogenomic update on two types of multiple sclerosis therapy.Pharmacogenomics and multiple sclerosis: moving toward individualized medicine.Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases.Integrative genomics strategies to elucidate the complexity of drug response.Pharmacogenomics in neurology: current state and future steps.Single nucleotide polymorphisms in multiple sclerosis: disease susceptibility and treatment response biomarkers.Pharmacogenomic update on multiple sclerosis: a focus on actual and new therapeutic strategies.Current developments in pharmacogenomics of multiple sclerosis.Pharmacogenetic Biomarkers to Predict Treatment Response in Multiple Sclerosis: Current and Future Perspectives.ZFAT is essential for endothelial cell assembly and the branch point formation of capillary-like structures in an angiogenesis model.A cytokine gene screen uncovers SOCS1 as genetic risk factor for multiple sclerosis.HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis.Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.Genome-wide association analysis of age at onset in schizophrenia in a European-American sample.Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis.Polymorphisms of innate pattern recognition receptors, response to interferon-beta and development of neutralizing antibodies in multiple sclerosis patients.BiomarkersAllelic combinations of immune-response genes as possible composite markers of IFN-β efficacy in multiple sclerosis patientsZfat expression in ZsGreen reporter gene knock‑in mice: Implications for a novel function of Zfat in definitive erythropoiesis
P2860
Q28261215-B611D96C-4610-423D-AEF6-F08B347F6614Q28513768-946D20B9-48BE-44CF-9793-50251224A99CQ30795448-B5D173AB-7FC1-46B1-BC32-7169DCBE591AQ33791354-CE577B7C-981C-466E-8984-2818E042CA70Q33796163-6F3BF11D-1A55-41DD-B2D6-FB1A746A8BC6Q34415006-23EBCCB1-BFAF-4719-A298-2F8C1B724669Q34612307-1584ACB4-1D41-41FF-A844-2EF100BE16C4Q34712125-58F6B352-2611-4B90-B926-AD267EDAF092Q34790668-F7EEBE8F-5EBB-4D5B-89FA-7D7431699BE2Q34979385-DAE5F1F0-1A0C-420F-859E-3F79CCEDE1FAQ35009304-DCA6C33A-7709-4648-A602-54E32C2D15E4Q35846494-745AF68F-27B4-41FA-B0FC-F60AFF781B6DQ35847422-C5C24C08-7BB4-4E7A-B6BD-2689E20DDAD4Q36001691-BD222995-8B8E-4619-8742-6118C3853B3CQ36059972-B8A87EE2-6C68-46A1-8942-28A2A1E5484EQ36092690-EBB42CC6-6C6B-42C5-8C34-1BB405929702Q37098954-788E4BDE-8B6B-49D5-A0F9-CBB0AF158727Q37297647-06038000-7E37-410C-85DD-B072B1742958Q37780222-EA1912B7-894C-42A7-9F1B-4F6FE1EA0CF7Q37830727-088BC888-80B8-4428-99BD-CB2CC9925B8EQ37848651-8C99442F-89F4-42E4-97B6-E6737856E099Q37859376-02F9A4D5-0720-4756-8CA0-CE874634E08EQ37893991-54CEE613-7B78-4E51-B103-D884A3C4D6A1Q37946958-A6CA064B-F8A2-4DF8-A897-44FFBDD6C497Q37961088-1A521B73-E8F6-42D3-AE22-6475476CBF76Q37967607-CA5825D6-4A6D-47A0-8075-BA909F25804FQ37990779-BE917059-D09D-44C9-B1BF-76B47DEF9598Q38050313-BA76805B-5E2B-4111-88D6-952AA0777DA6Q38239501-52949356-A676-4F68-AAFA-7902F2D1457DQ38643129-F18CC3B2-79FD-4E96-AC1F-733490A4A2B9Q39678166-88D6E8C7-EAEE-4FC5-8735-A4EDC015C644Q44596853-A0052957-1BE2-4A49-BC33-1756DD68B154Q45801403-1FC4683E-0768-41C2-9BC9-267B7EB04B2EQ51089837-305E9981-C3B9-4DE8-97AE-7415E0D23B99Q51448262-2FC31D4F-0272-480A-A11C-192CC6578E9EQ52897470-3AD1281B-2AD7-44C7-AF51-D7F0859562D4Q54665285-11F89C56-8CA8-4086-95A7-200944EB71A9Q57083573-BDF71F49-176A-4C19-95FC-053794027658Q57417460-51B65EE0-68C5-4FF6-8E4E-5531453459D7Q58800735-E6767ED3-97A5-4F83-92B0-DE94E38C5A90
P2860
Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Genome-wide scan of 500,000 si ...... therapy in multiple sclerosis.
@en
Genome-wide scan of 500,000 si ...... therapy in multiple sclerosis.
@nl
type
label
Genome-wide scan of 500,000 si ...... therapy in multiple sclerosis.
@en
Genome-wide scan of 500,000 si ...... therapy in multiple sclerosis.
@nl
prefLabel
Genome-wide scan of 500,000 si ...... therapy in multiple sclerosis.
@en
Genome-wide scan of 500,000 si ...... therapy in multiple sclerosis.
@nl
P2093
P50
P1433
P1476
Genome-wide scan of 500,000 si ...... therapy in multiple sclerosis
@en
P2093
Arcadi Navarro
Carlos Morcillo-Suárez
David W Craig
Manuel Comabella
Marta Fernández
P304
P356
10.1001/ARCHNEUROL.2009.150
P577
2009-08-01T00:00:00Z